289 related articles for article (PubMed ID: 24395247)
1. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53.
Kelly GL; Grabow S; Glaser SP; Fitzsimmons L; Aubrey BJ; Okamoto T; Valente LJ; Robati M; Tai L; Fairlie WD; Lee EF; Lindstrom MS; Wiman KG; Huang DC; Bouillet P; Rowe M; Rickinson AB; Herold MJ; Strasser A
Genes Dev; 2014 Jan; 28(1):58-70. PubMed ID: 24395247
[TBL] [Abstract][Full Text] [Related]
2. Loss of a Single Mcl-1 Allele Inhibits MYC-Driven Lymphomagenesis by Sensitizing Pro-B Cells to Apoptosis.
Grabow S; Delbridge AR; Aubrey BJ; Vandenberg CJ; Strasser A
Cell Rep; 2016 Mar; 14(10):2337-47. PubMed ID: 26947081
[TBL] [Abstract][Full Text] [Related]
3. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
4. Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death.
Domostegui A; Peddigari S; Mercer CA; Iannizzotto F; Rodriguez ML; Garcia-Cajide M; Amador V; Diepstraten ST; Kelly GL; Salazar R; Kozma SC; Kusnadi EP; Kang J; Gentilella A; Pearson RB; Thomas G; Pelletier J
Blood; 2021 Jun; 137(24):3351-3364. PubMed ID: 33512431
[TBL] [Abstract][Full Text] [Related]
5. Critical B-lymphoid cell intrinsic role of endogenous MCL-1 in c-MYC-induced lymphomagenesis.
Grabow S; Kelly GL; Delbridge AR; Kelly PN; Bouillet P; Adams JM; Strasser A
Cell Death Dis; 2016 Mar; 7(3):e2132. PubMed ID: 26962682
[TBL] [Abstract][Full Text] [Related]
6. MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice.
Grabow S; Delbridge AR; Valente LJ; Strasser A
Blood; 2014 Dec; 124(26):3939-46. PubMed ID: 25368374
[TBL] [Abstract][Full Text] [Related]
7. Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.
Campbell KJ; Bath ML; Turner ML; Vandenberg CJ; Bouillet P; Metcalf D; Scott CL; Cory S
Blood; 2010 Oct; 116(17):3197-207. PubMed ID: 20631380
[TBL] [Abstract][Full Text] [Related]
8. p53 and p73 in suppression of Myc-driven lymphomagenesis.
Griesmann H; Schlereth K; Krause M; Samans B; Stiewe T
Int J Cancer; 2009 Jan; 124(2):502-6. PubMed ID: 18942718
[TBL] [Abstract][Full Text] [Related]
9. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
[TBL] [Abstract][Full Text] [Related]
10. Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs.
Happo L; Phipson B; Smyth GK; Strasser A; Scott CL
Cell Death Dis; 2012 May; 3(5):e306. PubMed ID: 22573037
[TBL] [Abstract][Full Text] [Related]
11. IBTK contributes to B-cell lymphomagenesis in Eμ-myc transgenic mice conferring resistance to apoptosis.
Vecchio E; Golino G; Pisano A; Albano F; Falcone C; Ceglia S; Iaccino E; Mimmi S; Fiume G; Giurato G; Britti D; Scala G; Quinto I
Cell Death Dis; 2019 Apr; 10(4):320. PubMed ID: 30975981
[TBL] [Abstract][Full Text] [Related]
12. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
Hemann MT; Bric A; Teruya-Feldstein J; Herbst A; Nilsson JA; Cordon-Cardo C; Cleveland JL; Tansey WP; Lowe SW
Nature; 2005 Aug; 436(7052):807-11. PubMed ID: 16094360
[TBL] [Abstract][Full Text] [Related]
13. Bim must be able to engage all pro-survival Bcl-2 family members for efficient tumor suppression.
Mérino D; Strasser A; Bouillet P
Oncogene; 2012 Jul; 31(28):3392-6. PubMed ID: 22081075
[TBL] [Abstract][Full Text] [Related]
14. A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 3' regulatory region-driven c-myc transgene.
Fiancette R; Rouaud P; Vincent-Fabert C; Laffleur B; Magnone V; Cogné M; Denizot Y
J Immunol; 2011 Dec; 187(11):5772-82. PubMed ID: 22039300
[TBL] [Abstract][Full Text] [Related]
15. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas.
Mason KD; Vandenberg CJ; Scott CL; Wei AH; Cory S; Huang DC; Roberts AW
Proc Natl Acad Sci U S A; 2008 Nov; 105(46):17961-6. PubMed ID: 19004807
[TBL] [Abstract][Full Text] [Related]
16. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
17. Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice.
Kelly PN; Grabow S; Delbridge AR; Strasser A; Adams JM
Blood; 2011 Dec; 118(24):6380-6. PubMed ID: 21998213
[TBL] [Abstract][Full Text] [Related]
18. Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss.
Baudino TA; Maclean KH; Brennan J; Parganas E; Yang C; Aslanian A; Lees JA; Sherr CJ; Roussel MF; Cleveland JL
Mol Cell; 2003 Apr; 11(4):905-14. PubMed ID: 12718877
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor-β directly induces p53-up-regulated modulator of apoptosis (PUMA) during the rapid induction of apoptosis in myc-driven B-cell lymphomas.
Spender LC; Carter MJ; O'Brien DI; Clark LJ; Yu J; Michalak EM; Happo L; Cragg MS; Inman GJ
J Biol Chem; 2013 Feb; 288(7):5198-209. PubMed ID: 23243310
[TBL] [Abstract][Full Text] [Related]
20. Addiction to Runx1 is partially attenuated by loss of p53 in the Eµ-Myc lymphoma model.
Borland G; Kilbey A; Hay J; Gilroy K; Terry A; Mackay N; Bell M; McDonald A; Mills K; Cameron E; Neil JC
Oncotarget; 2016 Apr; 7(17):22973-87. PubMed ID: 27056890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
